Tretinoin
( DrugBank: Tretinoin / KEGG DRUG: Tretinoin )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
| 62 | Paroxysmal nocturnal hemoglobinuria | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 63 | Idiopathic thrombocytopenic purpura | 1 |
| 75 | Cushing disease | 2 |
2. Amyotrophic lateral sclerosis
Clinical trials : 867 / Drugs : 820 - (DrugBank : 185) / Drug target genes : 189 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
62. Paroxysmal nocturnal hemoglobinuria
Clinical trials : 380 / Drugs : 240 - (DrugBank : 38) / Drug target genes : 28 - Drug target pathways : 122
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
63. Idiopathic thrombocytopenic purpura
Clinical trials : 868 / Drugs : 544 - (DrugBank : 96) / Drug target genes : 82 - Drug target pathways : 195
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
75. Cushing disease
Clinical trials : 231 / Drugs : 224 - (DrugBank : 47) / Drug target genes : 63 - Drug target pathways : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
